Cargando…
Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections
BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137218/ https://www.ncbi.nlm.nih.gov/pubmed/35686240 http://dx.doi.org/10.22122/arya.v17i0.2191 |
_version_ | 1784714330680328192 |
---|---|
author | Safarnezhad-Tameshkel, Fahimeh Motamed, Nima Karbalaie Niya, Mohammad Hadi Perumal, Dhayaneethie Rezaie, Nader Izadi, Shirin Ranjbar, Mitra Yadollahzadeh, Mahdi Behdad, Behnam Hemmasi, Gholamreza Kaveh, Vahid Anoushirvani, Ali Arash Malek, Mojtaba Farahani, Behzad Eskandari, Ramin Panahi, Mahshid Rahimi, Mandana Emami, Sepideh Zamani, Farhad Farrokhpour, Mohsen |
author_facet | Safarnezhad-Tameshkel, Fahimeh Motamed, Nima Karbalaie Niya, Mohammad Hadi Perumal, Dhayaneethie Rezaie, Nader Izadi, Shirin Ranjbar, Mitra Yadollahzadeh, Mahdi Behdad, Behnam Hemmasi, Gholamreza Kaveh, Vahid Anoushirvani, Ali Arash Malek, Mojtaba Farahani, Behzad Eskandari, Ramin Panahi, Mahshid Rahimi, Mandana Emami, Sepideh Zamani, Farhad Farrokhpour, Mohsen |
author_sort | Safarnezhad-Tameshkel, Fahimeh |
collection | PubMed |
description | BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease. METHODS: The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19. RESULTS: The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004). CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The periodical assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians. |
format | Online Article Text |
id | pubmed-9137218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-91372182022-06-08 Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections Safarnezhad-Tameshkel, Fahimeh Motamed, Nima Karbalaie Niya, Mohammad Hadi Perumal, Dhayaneethie Rezaie, Nader Izadi, Shirin Ranjbar, Mitra Yadollahzadeh, Mahdi Behdad, Behnam Hemmasi, Gholamreza Kaveh, Vahid Anoushirvani, Ali Arash Malek, Mojtaba Farahani, Behzad Eskandari, Ramin Panahi, Mahshid Rahimi, Mandana Emami, Sepideh Zamani, Farhad Farrokhpour, Mohsen ARYA Atheroscler Original Article BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease. METHODS: The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19. RESULTS: The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004). CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The periodical assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians. Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2021-09 /pmc/articles/PMC9137218/ /pubmed/35686240 http://dx.doi.org/10.22122/arya.v17i0.2191 Text en © 2021 Isfahan Cardiovascular Research Center & Isfahan University of Medical Sciences https://creativecommons.org/licenses/by-nc/3.0/This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Safarnezhad-Tameshkel, Fahimeh Motamed, Nima Karbalaie Niya, Mohammad Hadi Perumal, Dhayaneethie Rezaie, Nader Izadi, Shirin Ranjbar, Mitra Yadollahzadeh, Mahdi Behdad, Behnam Hemmasi, Gholamreza Kaveh, Vahid Anoushirvani, Ali Arash Malek, Mojtaba Farahani, Behzad Eskandari, Ramin Panahi, Mahshid Rahimi, Mandana Emami, Sepideh Zamani, Farhad Farrokhpour, Mohsen Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections |
title | Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections |
title_full | Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections |
title_fullStr | Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections |
title_full_unstemmed | Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections |
title_short | Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections |
title_sort | troponin is a useful marker in clinical decision making in hospitalized patients with covid-19 infections |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137218/ https://www.ncbi.nlm.nih.gov/pubmed/35686240 http://dx.doi.org/10.22122/arya.v17i0.2191 |
work_keys_str_mv | AT safarnezhadtameshkelfahimeh troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT motamednima troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT karbalaieniyamohammadhadi troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT perumaldhayaneethie troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT rezaienader troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT izadishirin troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT ranjbarmitra troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT yadollahzadehmahdi troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT behdadbehnam troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT hemmasigholamreza troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT kavehvahid troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT anoushirvanialiarash troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT malekmojtaba troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT farahanibehzad troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT eskandariramin troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT panahimahshid troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT rahimimandana troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT emamisepideh troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT zamanifarhad troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections AT farrokhpourmohsen troponinisausefulmarkerinclinicaldecisionmakinginhospitalizedpatientswithcovid19infections |